Under liquidation, owners and financials
CVR: 39119374
Previous names: Embark Biotech IvS, Embark Biotech ApS, Novo Nordisk Research Center Gladsaxe ApS
DKK -1,000
Gross profit
Net result: DKK 48,000
NOVO NORDISK A/S (100%)
CVR · view owners
Anders Ørjan Jensen
CVR · view management
Under liquidation
Founded 28 November 2017
CVR · view overview
7 employees
CVR · 2023
Name registered: Anpartsselskabet af 21.08.2026
CVR · 21/08/2026
View the full event history
Anpartsselskabet af 21.08.2026 is a Danish company of the type Anpartsselskab based in København V, founded in 2017. The company is in liquidation. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Novo Nordisk Research Center Gladsaxe ApS and Embark Biotech ApS. The management consists of Anders Ørjan Jensen. The company is owned by NOVO NORDISK A/S. The company has 7 employees (2023). In 2025, the company reported a gross profit of DKK -1,000 and a net result of DKK 48,000 compared with DKK 6,174,000 the year before. Equity in the 2025 report amounted to DKK 807,000.
Selskabets formål er at udføre forskning, udvikling og støtte kliniske forsøg af farmaceutiske produkter og at markedsføre, promovere, sælge og distribuere farmaceutiske og medicinske produkter samt enhver anden aktivitet i forbindelse hermed. Endvidere er selskabets formål at understøtte Novo Nordisk A/S' farmaceutiske aktiviteter. Selskabet bestræber sig på at udføre sine aktiviteter på en økonomisk, miljømæssig og socialt ansvarlig måde.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -1 t. | 48 t. | 833 t. | 807 t. | 0 | |
| 202401/01/2024 – 31/12/2024 | -38 t. | 6.2 mio. | 8.5 mio. | 6.8 mio. | 0 | |
| 202301/01/2023 – 31/12/2023 | - | 395.5 mio. | 517 mio. | 405.6 mio. | 2 | |
| 202201/01/2022 – 31/12/2022 | 379 t. | -8.8 mio. | 7.8 mio. | -5.9 mio. | 4 | |
| 202101/01/2021 – 31/12/2021 | 0 | -6.2 mio. | 10.7 mio. | 2.9 mio. | 3 | |
| 202001/01/2020 – 31/12/2020 | 10.7 mio. | 3.2 mio. | 11.7 mio. | 9.5 mio. | 5 | |
| 201901/01/2019 – 31/12/2019 | 25.6 mio. | 14.4 mio. | 28.2 mio. | 18.3 mio. | 5 | |
| 201828/11/2017 – 31/12/2018 | 14.9 mio. | 9.8 mio. | - | 52 t. | 1 |
Compared to 1.039 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAnpartsselskabet af 21.08.2026 is registered in the Danish CVR register with the status Under liquidation.
The CVR number of Anpartsselskabet af 21.08.2026 is 39119374.
Anpartsselskabet af 21.08.2026 is owned by NOVO NORDISK A/S.
The management of Anpartsselskabet af 21.08.2026 consists of Anders Ørjan Jensen.
In 2025, Anpartsselskabet af 21.08.2026 reported a gross profit of DKK -1,000.
Anpartsselskabet af 21.08.2026 had 7 employees in 2023 according to the Danish CVR register.
On September 7, 2026, Anpartsselskabet af 21.08.2026 entered liquidation.
Address changed to Axeltorv 2, 1609 København V (September 4, 2026).
As of August 21, 2026, Peter Bøggild has left the board of directors of Anpartsselskabet af 21.08.2026.
As of August 21, 2026, Kristine Aachmann Bethe has left the board of directors of Anpartsselskabet af 21.08.2026.
As of August 21, 2026, Anders Ørjan Jensen is registered as liquidator of Anpartsselskabet af 21.08.2026.
As of August 21, 2026, Rikke Ryttergaard Winstrøm Andersen has stepped down as adm. dir. of Anpartsselskabet af 21.08.2026.
On August 21, 2026, the company changed its name from Novo Nordisk Research Center Gladsaxe ApS to Anpartsselskabet af 21.08.2026.
On August 21, 2026, Anpartsselskabet af 21.08.2026 entered liquidation.
Anpartsselskabet af 21.08.2026 has published its annual report for 2025. Gross profit came to DKK -1,000, and the net result was DKK 48,000.
As of May 29, 2026, EY Godkendt Revisionspartnerselskab has stepped down as auditor of Anpartsselskabet af 21.08.2026.
As of December 3, 2025, Rikke Ryttergaard Winstrøm Andersen is registered as adm. dir. of Anpartsselskabet af 21.08.2026.
As of December 3, 2025, Trine Haastrup has stepped down as director of Anpartsselskabet af 21.08.2026.
Anpartsselskabet af 21.08.2026 has published its annual report for 2024. Gross profit came to DKK -38,000, and the net result was DKK 6,174,000.
Anpartsselskabet af 21.08.2026 has published its annual report for 2023. The net result was DKK 395,475,000.
As of August 29, 2023, Peter Bøggild has joined the board of directors of Anpartsselskabet af 21.08.2026.
As of August 29, 2023, Kristine Aachmann Bethe has joined the board of directors of Anpartsselskabet af 21.08.2026.
As of August 29, 2023, Casper Tind Hansen has left the board of directors of Anpartsselskabet af 21.08.2026.
As of August 29, 2023, Klaus Christian Schollmeier has left the board of directors of Anpartsselskabet af 21.08.2026.
As of August 29, 2023, Trine Haastrup is registered as director of Anpartsselskabet af 21.08.2026.
As of August 29, 2023, Casper Tind Hansen has stepped down as adm. dir. of Anpartsselskabet af 21.08.2026.
As of August 29, 2023, Jakob Bondo Hansen has stepped down as director of Anpartsselskabet af 21.08.2026.
On August 29, 2023, the company changed its name from Embark Biotech ApS to Novo Nordisk Research Center Gladsaxe ApS.
As of August 29, 2023, NOVO NORDISK A/S is registered as an owner of Anpartsselskabet af 21.08.2026 with an ownership share of 100%.
Anpartsselskabet af 21.08.2026 has published its annual report for 2022. Gross profit came to DKK 379,438, and the net result was DKK -8,830,214.
Anpartsselskabet af 21.08.2026 has published its annual report for 2021. Gross profit came to DKK 0, and the net result was DKK -6,196,311.
As of August 9, 2021, Casper Tind Hansen has joined the board of directors of Anpartsselskabet af 21.08.2026.
As of August 9, 2021, Klaus Christian Schollmeier has joined the board of directors of Anpartsselskabet af 21.08.2026.
As of August 9, 2021, Jakob Bondo Hansen is registered as director of Anpartsselskabet af 21.08.2026.
Anpartsselskabet af 21.08.2026 has published its annual report for 2020. Gross profit came to DKK 10,676,598, and the net result was DKK 3,185,064.
Anpartsselskabet af 21.08.2026 has published its annual report for 2019. Gross profit came to DKK 25,623,833, and the net result was DKK 14,426,111.
Anpartsselskabet af 21.08.2026 has published its annual report for 2018. Gross profit came to DKK 14,947,235, and the net result was DKK 9,820,500.
As of May 21, 2019, EY Godkendt Revisionspartnerselskab has been appointed auditor of Anpartsselskabet af 21.08.2026.
On August 15, 2018, the company changed its name from Embark Biotech IvS to Embark Biotech ApS.
As of November 28, 2017, Casper Tind Hansen is registered as adm. dir. of Anpartsselskabet af 21.08.2026.
Anpartsselskabet af 21.08.2026 was founded on November 28, 2017.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Companies in the same industry and area
CVR 44695065
CVR 46314964
CVR 40172076
CVR 45011879
CVR 46496981
